Literature DB >> 27423448

Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature.

J A Moody1, R F Ali1, A C Carbone2, S Singh2, J T Hardwicke3.   

Abstract

PURPOSE: The complications reported after sentinel lymph node biopsy (SLNB) for melanoma is highly variable in the worldwide literature; the overall complication rate varies between 1.8% and 29.9%. With heterogeneous reporting of morbidity data, no 'average' complication rates of this procedure have been reported. This systematic review aims to determine the complications rates associated with SLNB.
METHODS: A systematic review of English-language literature from 2000 to 2015, which reported morbidity information about SLNB for melanoma, was performed. The methodological quality of the included studies was performed using the methodological index for non-randomised studies (MINORS) instrument and Detsky score. Pooled proportions of specific post-operative complications were constructed using a random effects statistical model, and subgroups including lymph node basin and continent of origin of the study were compared.
RESULTS: After application of inclusion and exclusion criteria, 21 articles progressed to the final analysis. 9047 patients were included. The overall complication rate was 11.3% (95% CI: 8.1-15.0). The incidence of infection was 2.9% (95% CI 1.5-4.6); seroma 5.1% (95% CI: 2.5-8.6); haematoma 0.5% (95% CI: 0.3-0.9) lymphoedema 1.3% (95% CI: 0.5-2.6) and nerve injury 0.3% (95% CI: 0.1-0.6). There was no statistically significant difference in morbidity between the sites of SLNB or between continents. DISCUSSION: This study provides information about the incidence of complications after SLNB. It can be used to counsel patients about the procedure and it sets a benchmark against which surgeons can audit their practice. Crown
Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biopsy; Complications; Haematoma; Infection; Lymph node; Lymphoedema; Melanoma; Sentinel; Seroma

Mesh:

Year:  2016        PMID: 27423448     DOI: 10.1016/j.ejso.2016.06.407

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  14 in total

Review 1.  Nodal staging of high-risk cutaneous squamous cell carcinoma.

Authors:  Matthew Fox; Marc Brown; Nicholas Golda; Dori Goldberg; Christopher Miller; Melissa Pugliano-Mauro; Chrysalyne Schmults; Thuzar Shin; Thomas Stasko; Yaohui G Xu; Kishwer Nehal
Journal:  J Am Acad Dermatol       Date:  2018-09-15       Impact factor: 11.527

2.  Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma.

Authors:  Ferdinand Toberer; Holger A Haenssle; Martin Laimer; Monika Heinzel-Gutenbrunner; Alexander Enk; Wolfgang Hartschuh; Peter Helmbold; Heinz Kutzner
Journal:  Acta Derm Venereol       Date:  2020-08-18       Impact factor: 3.875

3.  Case Report: Breast Seroma Mimicking Breast Implants.

Authors:  Amalie Sylvester-Hvid; Magnus B Avnstorp; Lene Wagenblast; Jørgen Lock-Andersen; Steen H Matzen
Journal:  Int J Surg Case Rep       Date:  2017-09-04

4.  Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.

Authors:  Domenico Bellomo; Suzette M Arias-Mejias; Chandru Ramana; Joel B Heim; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Mark R Pittelkow; David J DiCaudo; Barbara A Pockaj; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves
Journal:  JCO Precis Oncol       Date:  2020-04-14

5.  Gamma probe and ultrasound-guided fine needle aspiration cytology of the sentinel node (GULF) trial.

Authors:  Daniëlle Verver; Charlotte M C Oude Ophuis; Lisa B Koppert; Cécile de Monyé; Carolien H M van Deurzen; Senada Koljenović; Annemarie Bruining; Bernies van der Hiel; Sylvia Ter Meulen; Alexander C J van Akkooi; Cornelis Verhoef; Dirk J Grünhagen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-26       Impact factor: 9.236

Review 6.  Sentinel lymph node biopsy in melanoma: beyond histologic factors.

Authors:  Michael J Carr; Federico A Monzon; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2021-06-08       Impact factor: 5.150

7.  Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.

Authors:  Tina J Hieken; Mariana B Sadurní; Enrica Quattrocchi; Ajdin Kobic; Sindhuja Sominidi-Damodaran; Jvalini T Dwarkasing; Lisette Meerstein-Kessel; Alina G Bridges; Alexander Meves
Journal:  Int J Dermatol       Date:  2022-01-31       Impact factor: 3.204

8.  Deselecting Melanoma Patients for Sentinel Lymph Node Biopsy During COVID-19: Clinical Utility of Tumor Molecular Profiling.

Authors:  Alexander Meves; Alexander M M Eggermont
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2020-07-17

9.  The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study.

Authors:  Alyss V Robinson; Claire Keeble; Michelle C I Lo; Owen Thornton; Howard Peach; Marc D S Moncrieff; Donald J Dewar; Ryckie G Wade
Journal:  Cancer Immunol Immunother       Date:  2020-01-23       Impact factor: 6.968

10.  Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Authors:  E E A P Mulder; J T Dwarkasing; D Tempel; A van der Spek; L Bosman; D Verver; A L Mooyaart; A A M van der Veldt; C Verhoef; T E C Nijsten; D J Grunhagen; L M Hollestein
Journal:  Br J Dermatol       Date:  2020-11-02       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.